Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Investing Activities (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Cash from Investing Activities for 14 consecutive years, with -$5.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 147.78% year-over-year to -$5.5 million, compared with a TTM value of $16.0 million through Dec 2025, down 14.45%, and an annual FY2025 reading of $16.0 million, down 14.45% over the prior year.
  • Cash from Investing Activities was -$5.5 million for Q4 2025 at Heron Therapeutics, down from $11.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $39.7 million in Q2 2021 and bottomed at -$36.0 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is $4.1 million, with a median of $3.1 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities soared 351.98% in 2022, then plummeted 537.21% in 2023.
  • Year by year, Cash from Investing Activities stood at -$24.3 million in 2021, then soared by 108.33% to $2.0 million in 2022, then tumbled by 537.21% to -$8.8 million in 2023, then skyrocketed by 229.22% to $11.4 million in 2024, then crashed by 147.78% to -$5.5 million in 2025.
  • Business Quant data shows Cash from Investing Activities for HRTX at -$5.5 million in Q4 2025, $11.9 million in Q3 2025, and $7.3 million in Q2 2025.